Translational Research Network for Prostate Cancer.
Training programme designed to tackle uncurable prostate cancer.
Human R&D, Training
H2020-MSCA-ITN-2016 – Grant Agreement ID 721746
1 Jan 2017 to 31 December 2021
Prostate cancer (PCa) is the most commonly diagnosed cancer in Europe and is the third most common cause of cancer death. First-line therapy for PCa is androgen deprivation therapy (ADT), however after around two or three years, resistance to this treatment manifests leading to castration-resistant prostate cancer (CRPC). CRPC is more metastatic and aggressive, and further treatment via chemotherapy gives only a modest survival benefit to patients. There is therefore an urgent need for more effective novel therapies for incurable PCa. The TransPot scientific objective therefore, is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PCa, aimed to 1) provide important insights into molecular mechanisms driving treatment resistant PCa including castrate-resistant PCa (CRPC), 2) identify novel therapeutic targets, 3) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and 4) provide superior, clinically relevant tools and biomarker signatures for personalizing and optimizing CRPC therapy. The programme integrates the leading research scientists and industrial institutions in this field within Europe to train 11 early stage researchers (ESRs) to become the next expert in Prostate Cancer research. GenomeScan, through training of two ESRs, hosting multiple secondments, and providing Next Generation Sequencing (NGS) services and computational analyses, investigates the transcriptomes of both patients and preclinical disease models for biomarker discovery and biomarker-based assay development.
T.b.a. (ongoing project)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 721746.